Accelus terminated merger with CHP Merger in a $482m deal.

Accelus, a commercial stage medical technology company, terminated merger with CHP Merger, a special purpose acquisition company formed by an affiliate of Concord Health Partners, in a $482m deal. "In light of market conditions, we believe that this strategic pivot will best enable our team to execute on our mission to transform the spine surgery space by accelerating the adoption of MIS as the standard of care. We continue to see accelerating demand for our highly differentiated product portfolio, and for robotic-enabled minimally invasive techniques specifically, both in hospitals and ASCs. As we look ahead, I am confident that our team is more focused than ever on addressing critical constraints related to cost and efficiency and on fulfilling a significant unmet need. We are grateful for the support we have received from the CHP team and their enduring commitment to advancing MIS spine surgery," Chris Walsh, Accelus CEO.